In the past, patients with hepatitis B virus (also known as HBV) were often recommended to take continuous, lifelong medication, with adherence to a regular schedule of follow-up visits. The goals of these specific drugs are to reduce the risk of severe disease progression and to help prevent the virus transmission to others.
Recently, HBcrAg has been introduced and utilized in clinical practice and become a decisive factor to tell when it is appropriate to stop treatment. This is a good sign for patients having HBV and using medications in a long time.